First ever scientific advice for patient preference study from British HTA authority


The British National Institute for Health and Care Excellence (NICE) recently provided its first piece of advice on a patient preference study design. The advice was for Novartis, who are planning a patient preference study for people who are suffering from chronic obstructive pulmonary disease (COPD).

The NICE Scientific Advice team said they aim to encourage more companies to seek their advice for patient preference studies. Nigel Cook, Head of Decision Support & Insights, Global Patient Access at Novartis and also involved in PREFER, said:

“We see this engagement during the project design phase as a positive step, helping to ensure the results serve the interests of the different stakeholders: industry, NICE and the patient community”.

More on NICE website

Last modified: 2021-11-10